Evaluation of the Pharmacological Efficacy and Network Pharmacological Mechanisms of Total Lignans of Syringae Ramuls Against Liver Cancer
10.11969/j.issn.1673-548X.2025.03.018
- VernacularTitle:山沉香总木脂素抗肝癌的药效评价及网络药理学机制
- Author:
Yanhui REN
1
;
Cheng QU
;
Tuya BAI
Author Information
1. 010110 呼和浩特,内蒙古医科大学药学院
- Publication Type:Journal Article
- Keywords:
Network pharmacology;
Total lignans of syringae ramuls;
Liver cancer;
Flow cytometry;
Molecular docking
- From:
Journal of Medical Research
2025;54(3):95-102,136
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect and potential mechanism of total lignans of syringae ramuls(TLS)against liver cancer u-sing in vitro cellular assays,network pharmacological and molecular docking.Methods Flow cytometry was performed to detect the effect of TLS on apoptosis and cycle of HepG2 cells.TL components were collected by literature search;drug-like properties and synthetic scores of components were assessed by ADMETlab;toxicological parameters of components were predicted by ProTox-Ⅱ;TLS component targets were predicted by Swiss Target Prediction website;GeneCards,OMIM,DisGeNET,and PharmGKB databases were used to screen the related targets of liver cancer;The"component-disease-target"network diagram was constructed by Cytoscape software and the"protein-protein interaction"(PPI)network diagram was constructed by STRING platform;and DAVID database was used to analyse GO,KEGG and WIKI metabolic pathways.Results TLS at 50-200μg/ml could significantly inhibit the proliferation of HepG2 cells,induce apoptosis and block the cell cycle.The main components of TLS in anti-liver cancer were 31 active components,such as(-)matairesinol,(-)-secoisolariciresinol,and pinnatifolin A,which mainly acted on 82 key targets such as Akt1,Bel-2 and EGFR,which were mainly enriched in the cancer pathway,EGFR tyrosine kinase inhibitor resistance,cycle and apoptosis signaling pathways.Conclusion TLS may play an anti-liver cancer effect through multi-components,multi-targets,and multi-pathway.
